It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The incidence of kidney stones is increasing in the US population. Oxalate, a major factor for stone formation, is degraded by gut bacteria reducing its intestinal absorption. Intestinal O. formigenes colonization has been associated with a lower risk for recurrent kidney stones in humans. In the current study, we used a clinical trial of the eradication of Helicobacter pylori to assess the effects of an antibiotic course on O. formigenes colonization, urine electrolytes, and the composition of the intestinal microbiome. Of 69 healthy adult subjects recruited, 19 received antibiotics for H. pylori eradication, while 46 were followed as controls. Serial fecal samples were examined for O. formigenes presence and microbiota characteristics. Urine, collected serially fasting and following a standard meal, was tested for oxalate and electrolyte concentrations. O. formigenes prevalence was 50%. Colonization was significantly and persistently suppressed in antibiotic-exposed subjects but remained stable in controls. Urinary pH increased after antibiotics, but urinary oxalate did not differ between the control and treatment groups. In subjects not on antibiotics, the O. formigenes-positive samples had higher alpha-diversity and significantly differed in Beta-diversity from the O. formigenes-negative samples. Specific taxa varied in abundance in relation to urinary oxalate levels. These studies identified significant antibiotic effects on O. formigenes colonization and urinary electrolytes and showed that overall microbiome structure differed in subjects according to O. formigenes presence. Identifying a consortium of bacterial taxa associated with urinary oxalate may provide clues for the primary prevention of kidney stones in healthy adults.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 New York University, New York University Langone Health, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
2 New York University Langone Health, Vilcek Institute of Graduate Biomedical Sciences, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
3 New York University Langone Health, New York University, Division of Biostatistics, Department of Population Health, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)
4 The State University of New York, Korea, Department of Applied Mathematics and Statistics, Incheon, South Korea (GRID:grid.410685.e)
5 Rutgers University, Center for Advanced Biotechnology and Medicine, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)
6 Litholink Corp, Chicago, USA (GRID:grid.137628.9)
7 New York University, New York University Langone Health, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); Rutgers University, Center for Advanced Biotechnology and Medicine, Piscataway, USA (GRID:grid.430387.b) (ISNI:0000 0004 1936 8796)




